 | • レポートコード：D0GIR-01159 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、慢性閉塞性肺疾患（COPD）の世界市場を広く調査・分析し、今後の市場展望をまとめております。慢性閉塞性肺疾患（COPD）の種類別市場規模（短時間作用型気管支拡張剤、コルチコステロイド、メチルキサンチン、長時間作用型気管支拡張剤、ホスホジエステラーゼ4阻害剤、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：GSK、Ario Pharma、Novartis、Pfizer、Teva Pharmaceuticals、Merck、Ache、Boehringer Ingelheim、AstraZeneca、Roche、Almirall、Astellas Pharma、Aquinox Pharmaceuticals、Asmacure ・地域別グローバル市場分析 2015年-2020年 ・慢性閉塞性肺疾患（COPD）の北米市場（アメリカ、カナダ、メキシコ） ・慢性閉塞性肺疾患（COPD）のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・慢性閉塞性肺疾患（COPD）のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・慢性閉塞性肺疾患（COPD）の南米市場（ブラジル、アルゼンチン） ・慢性閉塞性肺疾患（COPD）の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：短時間作用型気管支拡張剤、コルチコステロイド、メチルキサンチン、長時間作用型気管支拡張剤、ホスホジエステラーゼ4阻害剤、その他 ・用途別分析：病院、クリニック、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global Chronic Obstructive Pulmonary Disorder market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Chronic Obstructive Pulmonary Disorder market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Chronic Obstructive Pulmonary Disorder market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Chronic Obstructive Pulmonary Disorder market has been segmented into:
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
By Application, Chronic Obstructive Pulmonary Disorder has been segmented into:
Hospitals
Clinics
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Chronic Obstructive Pulmonary Disorder market presented in the report. This section sheds light on the sales growth of different regional and country-level Chronic Obstructive Pulmonary Disorder markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Chronic Obstructive Pulmonary Disorder market.
The report offers in-depth assessment of the growth and other aspects of the Chronic Obstructive Pulmonary Disorder market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Chronic Obstructive Pulmonary Disorder Market Share Analysis
Chronic Obstructive Pulmonary Disorder competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Chronic Obstructive Pulmonary Disorder sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Chronic Obstructive Pulmonary Disorder sales, revenue and market share for each player covered in this report.
The major players covered in Chronic Obstructive Pulmonary Disorder are:
GSK
Ario Pharma
Novartis
Pfizer
Teva Pharmaceuticals
Merck
Ache
Boehringer Ingelheim
AstraZeneca
Roche
Almirall
Astellas Pharma
Aquinox Pharmaceuticals
Asmacure
Table of Contents
1 Chronic Obstructive Pulmonary Disorder Market Overview
1.1 Product Overview and Scope of Chronic Obstructive Pulmonary Disorder
1.2 Classification of Chronic Obstructive Pulmonary Disorder by Type
1.2.1 Global Chronic Obstructive Pulmonary Disorder Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Type in 2019
1.2.3 Short-Acting Bronchodilators
1.2.4 Corticosteroids
1.2.5 Methylxanthines
1.2.6 Long-Acting Bronchodilators
1.2.7 Phosphodiesterase-4 Inhibitors
1.2.8 Others
1.3 Global Chronic Obstructive Pulmonary Disorder Market by Application
1.3.1 Overview: Global Chronic Obstructive Pulmonary Disorder Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Chronic Obstructive Pulmonary Disorder Market by Regions
1.4.1 Global Chronic Obstructive Pulmonary Disorder Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Chronic Obstructive Pulmonary Disorder (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Chronic Obstructive Pulmonary Disorder Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Chronic Obstructive Pulmonary Disorder Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chronic Obstructive Pulmonary Disorder Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Chronic Obstructive Pulmonary Disorder Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chronic Obstructive Pulmonary Disorder Status and Prospect (2015-2025)
2 Company Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 GSK SWOT Analysis
2.1.4 GSK Product and Services
2.1.5 GSK Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.2 Ario Pharma
2.2.1 Ario Pharma Details
2.2.2 Ario Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Ario Pharma SWOT Analysis
2.2.4 Ario Pharma Product and Services
2.2.5 Ario Pharma Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Novartis SWOT Analysis
2.3.4 Novartis Product and Services
2.3.5 Novartis Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.5 Teva Pharmaceuticals
2.5.1 Teva Pharmaceuticals Details
2.5.2 Teva Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Teva Pharmaceuticals SWOT Analysis
2.5.4 Teva Pharmaceuticals Product and Services
2.5.5 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Merck SWOT Analysis
2.6.4 Merck Product and Services
2.6.5 Merck Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.7 Ache
2.7.1 Ache Details
2.7.2 Ache Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Ache SWOT Analysis
2.7.4 Ache Product and Services
2.7.5 Ache Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.8 Boehringer Ingelheim
2.8.1 Boehringer Ingelheim Details
2.8.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Boehringer Ingelheim SWOT Analysis
2.8.4 Boehringer Ingelheim Product and Services
2.8.5 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.9 AstraZeneca
2.9.1 AstraZeneca Details
2.9.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 AstraZeneca SWOT Analysis
2.9.4 AstraZeneca Product and Services
2.9.5 AstraZeneca Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.10 Roche
2.10.1 Roche Details
2.10.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Roche SWOT Analysis
2.10.4 Roche Product and Services
2.10.5 Roche Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.11 Almirall
2.11.1 Almirall Details
2.11.2 Almirall Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Almirall SWOT Analysis
2.11.4 Almirall Product and Services
2.11.5 Almirall Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.12 Astellas Pharma
2.12.1 Astellas Pharma Details
2.12.2 Astellas Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Astellas Pharma SWOT Analysis
2.12.4 Astellas Pharma Product and Services
2.12.5 Astellas Pharma Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.13 Aquinox Pharmaceuticals
2.13.1 Aquinox Pharmaceuticals Details
2.13.2 Aquinox Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Aquinox Pharmaceuticals SWOT Analysis
2.13.4 Aquinox Pharmaceuticals Product and Services
2.13.5 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
2.14 Asmacure
2.14.1 Asmacure Details
2.14.2 Asmacure Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Asmacure SWOT Analysis
2.14.4 Asmacure Product and Services
2.14.5 Asmacure Chronic Obstructive Pulmonary Disorder Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Chronic Obstructive Pulmonary Disorder Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Chronic Obstructive Pulmonary Disorder Players Market Share
3.2.2 Top 10 Chronic Obstructive Pulmonary Disorder Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Chronic Obstructive Pulmonary Disorder Revenue and Market Share by Regions
4.2 North America Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
4.3 Europe Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
4.5 South America Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
5 North America Chronic Obstructive Pulmonary Disorder Revenue by Countries
5.1 North America Chronic Obstructive Pulmonary Disorder Revenue by Countries (2015-2020)
5.2 USA Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
5.3 Canada Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
5.4 Mexico Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
6 Europe Chronic Obstructive Pulmonary Disorder Revenue by Countries
6.1 Europe Chronic Obstructive Pulmonary Disorder Revenue by Countries (2015-2020)
6.2 Germany Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
6.3 UK Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
6.4 France Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
6.5 Russia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
6.6 Italy Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue by Countries
7.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue by Countries (2015-2020)
7.2 China Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
7.3 Japan Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
7.4 Korea Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
7.5 India Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
8 South America Chronic Obstructive Pulmonary Disorder Revenue by Countries
8.1 South America Chronic Obstructive Pulmonary Disorder Revenue by Countries (2015-2020)
8.2 Brazil Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
8.3 Argentina Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Chronic Obstructive Pulmonary Disorder by Countries
9.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder Revenue by Countries (2015-2020)
9.2 Saudi Arabia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
9.3 UAE Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
9.4 Egypt Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
9.5 South Africa Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Chronic Obstructive Pulmonary Disorder Revenue and Market Share by Type (2015-2020)
10.2 Global Chronic Obstructive Pulmonary Disorder Market Forecast by Type (2019-2024)
10.3 Short-Acting Bronchodilators Revenue Growth Rate (2015-2025)
10.4 Corticosteroids Revenue Growth Rate (2015-2025)
10.5 Methylxanthines Revenue Growth Rate (2015-2025)
10.6 Long-Acting Bronchodilators Revenue Growth Rate (2015-2025)
10.7 Phosphodiesterase-4 Inhibitors Revenue Growth Rate (2015-2025)
10.8 Others Revenue Growth Rate (2015-2025)
11 Global Chronic Obstructive Pulmonary Disorder Market Segment by Application
11.1 Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Application (2015-2020)
11.2 Chronic Obstructive Pulmonary Disorder Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Others Revenue Growth (2015-2020)
12 Global Chronic Obstructive Pulmonary Disorder Market Size Forecast (2021-2025)
12.1 Global Chronic Obstructive Pulmonary Disorder Market Size Forecast (2021-2025)
12.2 Global Chronic Obstructive Pulmonary Disorder Market Forecast by Regions (2021-2025)
12.3 North America Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
12.4 Europe Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
12.6 South America Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Chronic Obstructive Pulmonary Disorder Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Chronic Obstructive Pulmonary Disorder by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Chronic Obstructive Pulmonary Disorder Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Chronic Obstructive Pulmonary Disorder Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. GSK Corporate Information, Location and Competitors
Table 6. GSK Chronic Obstructive Pulmonary Disorder Major Business
Table 7. GSK Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 8. GSK SWOT Analysis
Table 9. GSK Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 10. GSK Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Ario Pharma Corporate Information, Location and Competitors
Table 12. Ario Pharma Chronic Obstructive Pulmonary Disorder Major Business
Table 13. Ario Pharma Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2018-2019)
Table 14. Ario Pharma SWOT Analysis
Table 15. Ario Pharma Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 16. Ario Pharma Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Novartis Corporate Information, Location and Competitors
Table 18. Novartis Chronic Obstructive Pulmonary Disorder Major Business
Table 19. Novartis Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 20. Novartis SWOT Analysis
Table 21. Novartis Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 22. Novartis Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Pfizer Corporate Information, Location and Competitors
Table 24. Pfizer Chronic Obstructive Pulmonary Disorder Major Business
Table 25. Pfizer Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 26. Pfizer SWOT Analysis
Table 27. Pfizer Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 28. Pfizer Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Teva Pharmaceuticals Corporate Information, Location and Competitors
Table 30. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Major Business
Table 31. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 32. Teva Pharmaceuticals SWOT Analysis
Table 33. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 34. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Merck Corporate Information, Location and Competitors
Table 36. Merck Chronic Obstructive Pulmonary Disorder Major Business
Table 37. Merck Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 38. Merck SWOT Analysis
Table 39. Merck Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 40. Merck Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Ache Corporate Information, Location and Competitors
Table 42. Ache Chronic Obstructive Pulmonary Disorder Major Business
Table 43. Ache Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 44. Ache SWOT Analysis
Table 45. Ache Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 46. Ache Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Boehringer Ingelheim Corporate Information, Location and Competitors
Table 48. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Major Business
Table 49. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 50. Boehringer Ingelheim SWOT Analysis
Table 51. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 52. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. AstraZeneca Corporate Information, Location and Competitors
Table 54. AstraZeneca Chronic Obstructive Pulmonary Disorder Major Business
Table 55. AstraZeneca Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 56. AstraZeneca SWOT Analysis
Table 57. AstraZeneca Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 58. AstraZeneca Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Roche Corporate Information, Location and Competitors
Table 60. Roche Chronic Obstructive Pulmonary Disorder Major Business
Table 61. Roche Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 62. Roche SWOT Analysis
Table 63. Roche Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 64. Roche Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Almirall Corporate Information, Location and Competitors
Table 66. Almirall Chronic Obstructive Pulmonary Disorder Major Business
Table 67. Almirall Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 68. Almirall SWOT Analysis
Table 69. Almirall Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 70. Almirall Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Astellas Pharma Corporate Information, Location and Competitors
Table 72. Astellas Pharma Chronic Obstructive Pulmonary Disorder Major Business
Table 73. Astellas Pharma Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 74. Astellas Pharma SWOT Analysis
Table 75. Astellas Pharma Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 76. Astellas Pharma Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Aquinox Pharmaceuticals Corporate Information, Location and Competitors
Table 78. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Major Business
Table 79. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 80. Aquinox Pharmaceuticals SWOT Analysis
Table 81. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 82. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Asmacure Corporate Information, Location and Competitors
Table 84. Asmacure Chronic Obstructive Pulmonary Disorder Major Business
Table 85. Asmacure Chronic Obstructive Pulmonary Disorder Total Revenue (USD Million) (2017-2018)
Table 86. Asmacure SWOT Analysis
Table 87. Asmacure Chronic Obstructive Pulmonary Disorder Product and Solutions
Table 88. Asmacure Chronic Obstructive Pulmonary Disorder Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Global Chronic Obstructive Pulmonary Disorder Revenue (Million USD) by Players (2015-2020)
Table 90. Global Chronic Obstructive Pulmonary Disorder Revenue Share by Players (2015-2020)
Table 91. Global Chronic Obstructive Pulmonary Disorder Revenue (Million USD) by Regions (2015-2020)
Table 92. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Regions (2015-2020)
Table 93. North America Chronic Obstructive Pulmonary Disorder Revenue by Countries (2015-2020)
Table 94. North America Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries (2015-2020)
Table 95. Europe Chronic Obstructive Pulmonary Disorder Revenue (Million USD) by Countries (2015-2020)
Table 96. Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue (Million USD) by Countries (2015-2020)
Table 97. South America Chronic Obstructive Pulmonary Disorder Revenue by Countries (2015-2020)
Table 98. South America Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries (2015-2020)
Table 99. Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue (Million USD) by Countries (2015-2020)
Table 100. Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries (2015-2020)
Table 101. Global Chronic Obstructive Pulmonary Disorder Revenue (Million USD) by Type (2015-2020)
Table 102. Global Chronic Obstructive Pulmonary Disorder Revenue Share by Type (2015-2020)
Table 103. Global Chronic Obstructive Pulmonary Disorder Revenue Forecast by Type (2021-2025)
Table 104. Global Chronic Obstructive Pulmonary Disorder Revenue by Application (2015-2020)
Table 105. Global Chronic Obstructive Pulmonary Disorder Revenue Share by Application (2015-2020)
Table 106. Global Chronic Obstructive Pulmonary Disorder Revenue Forecast by Application (2021-2025)
Table 107. Global Chronic Obstructive Pulmonary Disorder Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Chronic Obstructive Pulmonary Disorder Picture
Figure 2. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Type in 2019
Figure 3. Short-Acting Bronchodilators Picture
Figure 4. Corticosteroids Picture
Figure 5. Methylxanthines Picture
Figure 6. Long-Acting Bronchodilators Picture
Figure 7. Phosphodiesterase-4 Inhibitors Picture
Figure 8. Others Picture
Figure 9. Chronic Obstructive Pulmonary Disorder Revenue Market Share by Application in 2019
Figure 10. Hospitals Picture
Figure 11. Clinics Picture
Figure 12. Others Picture
Figure 13. Global Chronic Obstructive Pulmonary Disorder Revenue (USD Million) and Growth Rate (2015-2025)
Figure 14. North America Chronic Obstructive Pulmonary Disorder Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Europe Chronic Obstructive Pulmonary Disorder Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. South America Chronic Obstructive Pulmonary Disorder Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Chronic Obstructive Pulmonary Disorder Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Chronic Obstructive Pulmonary Disorder Revenue Share by Players in 2019
Figure 21. Global Top 5 Players Chronic Obstructive Pulmonary Disorder Revenue Market Share in 2019
Figure 22. Global Top 10 Players Chronic Obstructive Pulmonary Disorder Revenue Market Share in 2019
Figure 23. Key Players Market Share Trend
Figure 24. Global Chronic Obstructive Pulmonary Disorder Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 25. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Regions (2015-2020)
Figure 26. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share by Regions in 2018
Figure 27. North America Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 28. Europe Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 29. Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 30. South America Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 31. Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 32. North America Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries (2015-2020)
Figure 33. North America Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries in 2019
Figure 34. USA Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 35. Canada Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 36. Mexico Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 37. Europe Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries (2015-2020)
Figure 38. Europe Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries in 2019
Figure 39. Germany Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 40. UK Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 41. France Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 42. Russia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 43. Italy Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries (2015-2020)
Figure 45. Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries in 2019
Figure 46. China Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 47. Japan Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 48. Korea Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 49. India Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 50. Southeast Asia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 51. South America Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries (2015-2020)
Figure 52. South America Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries in 2019
Figure 53. Brazil Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 54. Argentina Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 55. Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries (2015-2020)
Figure 56. Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue Market Share by Countries in 2019
Figure 57. Saudi Arabia Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 58. UAE Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 59. Egypt Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 60. South Africa Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2015-2020)
Figure 61. Global Chronic Obstructive Pulmonary Disorder Revenue Share by Type (2015-2020)
Figure 62. Global Chronic Obstructive Pulmonary Disorder Revenue Share by Type in 2019
Figure 63. Global Chronic Obstructive Pulmonary Disorder Market Share Forecast by Type (2021-2025)
Figure 64. Global Short-Acting Bronchodilators Revenue Growth Rate (2015-2020)
Figure 65. Global Corticosteroids Revenue Growth Rate (2015-2020)
Figure 66. Global Methylxanthines Revenue Growth Rate (2015-2020)
Figure 67. Global Long-Acting Bronchodilators Revenue Growth Rate (2015-2020)
Figure 68. Global Phosphodiesterase-4 Inhibitors Revenue Growth Rate (2015-2020)
Figure 69. Global Others Revenue Growth Rate (2015-2020)
Figure 70. Global Chronic Obstructive Pulmonary Disorder Revenue Share by Application (2015-2020)
Figure 71. Global Chronic Obstructive Pulmonary Disorder Revenue Share by Application in 2019
Figure 72. Global Chronic Obstructive Pulmonary Disorder Market Share Forecast by Application (2021-2025)
Figure 73. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 74. Global Clinics Revenue Growth Rate (2015-2020)
Figure 75. Global Others Revenue Growth Rate (2015-2020)
Figure 76. Global Chronic Obstructive Pulmonary Disorder Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 77. Global Chronic Obstructive Pulmonary Disorder Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 78. Global Chronic Obstructive Pulmonary Disorder Revenue Market Share Forecast by Regions (2021-2025)
Figure 79. North America Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
Figure 80. Europe Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
Figure 81. Asia-Pacific Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
Figure 82. South America Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
Figure 83. Middle East and Africa Chronic Obstructive Pulmonary Disorder Revenue Market Forecast (2021-2025)
Figure 84. Sales Channel: Direct Channel vs Indirect Channel
経カテーテル肺動脈弁置換術の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Transcatheter Pulmonary Valve Replacement market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value…- 脂質障害治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Lipid Disorder Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.1% in the forecast period of 2020 to 2025 and will expected to reach USD 26310 million by 2025, from USD 20740 million in 2019. The Lipid Disorde…
- 睡眠障害治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Sleep Disorder Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Sleep Disorder Th…
- 季節性情動障害治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Seasonal Affective Disorder Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Seasona…
- 神経障害薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Neurological Disorder Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.5% in the forecast period of 2020 to 2025 and will expected to reach USD 22730 million by 2025, from USD 19820 million in 2019. The Neurologic…